Rhône-Poulenc Rorer neuroscience news

The National Organization for Rare Disorders (NORD) selected an additional 1,000 people with amyotrophic lateral sclerosis (ALS) to receive RPR's Rilutek (riluzole) in the drug's early access program. A total of 2,250 ALS patients now are receiving the drug under the protocol. Patients who were not selected on July 24 were automatically reentered into the Aug. 24 computerized random selection process supervised by NORD. ...